COVID‐19 coagulopathy: An in‐depth analysis of the coagulation system

Abnormal coagulation parameters have been reported in COVID‐19‐infected patients. Although the underlying mechanism of COVID‐19 coagulopathy remains unknown, it has been suggested to be a form of disseminated intravascular coagulation (DIC).

[1]  M. Cecconi,et al.  Humanitas COVID-19 Task Force Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[2]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[3]  A. Dunn,et al.  Risk Factors for Mortality in Patients with COVID-19 in New York City , 2020, Journal of General Internal Medicine.

[4]  Toshiaki Iba,et al.  The unique characteristics of COVID-19 coagulopathy , 2020, Critical Care.

[5]  R. Schneider,et al.  Clinically significant anticardiolipin antibodies associated with COVID-19 , 2020, Journal of Critical Care.

[6]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[7]  P. Demelo-Rodríguez,et al.  Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism , 2020, Thrombosis Research.

[8]  P. Demelo-Rodríguez,et al.  Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels , 2020, Thrombosis Research.

[9]  J. Thachil,et al.  Coagulation abnormalities and thrombosis in patients with COVID-19 , 2020, The Lancet Haematology.

[10]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[11]  K. Mertz,et al.  Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction , 2020, Histopathology.

[12]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[13]  Tianyuan Wang,et al.  Cytokine storm intervention in the early stages of COVID-19 pneumonia , 2020, Cytokine & Growth Factor Reviews.

[14]  N. O'Connell,et al.  COVID19 coagulopathy in Caucasian patients , 2020, British journal of haematology.

[15]  C. Whyte,et al.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[16]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[17]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[18]  L. Beenen,et al.  Incidence of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[19]  L. Menicanti,et al.  The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome , 2020, Journal of Thrombosis and Haemostasis.

[20]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[21]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[22]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[23]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[24]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[25]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[26]  T. Hussell,et al.  Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers , 2018, European journal of immunology.

[27]  I. Jaunalksne,et al.  Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study , 2016, Front. Med..

[28]  Bobbie-Jo M. Webb-Robertson,et al.  Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury , 2013, mBio.

[29]  Y. Takei,et al.  Direct effects of protein S in ameliorating acute lung injury , 2009, Journal of thrombosis and haemostasis : JTH.

[30]  G. Espinosa,et al.  Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients , 2005, Annals of the rheumatic diseases.

[31]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[32]  D. Lillicrap,et al.  The Factor VIII Acute Phase Response Requires the Participation of NFκB and C/EBP , 2000, Thrombosis and Haemostasis.

[33]  T. van der Poll,et al.  TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. , 2014, Blood.

[34]  K. Fukutake,et al.  [Factor VII]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.